Clinical trial
The Efficacy and Safety of Aracmyn in Patients With Systemic Latrodectism
NCT00247078 · Instituto Bioclon S.A. de C.V., Industry · Completed
Key facts
| NCT number | NCT00247078 |
|---|---|
| Title | The Efficacy and Safety of Aracmyn in Patients With Systemic Latrodectism |
| Official title | The Efficacy and Safety of Aracmyn® [Antivenin Latrodectus (Black Widow)Equine Immune F(ab)2], in Patients With Systemic Latrodectism: A Phase II, Multi-center, Randomized, Double-Blind Trial |
| Lead sponsor | Instituto Bioclon S.A. de C.V., Industry |
| Collaborators | Rocky Mountain Poison and Drug Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Arachnidism, Latrodectism |
| Intervention type | Biological |
| Interventions | widow spider antivenom, Placebo |
| Enrollment | 24 |
| Start date | Oct 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Nov 1, 2005 |
| Last update posted | Mar 22, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: